Abstract
Obesity trends continue to rise in alarming proportions worldwide. Obstructive sleep apnea, an increasingly commonly recognized disorder, is characterized by recurrent episodes of upper airway closure during sleep, and obesity is proposed to be its strongest risk factor. Recognition strategies for OSA in obesity are overwhelmed by the sheer prevalence of obstructive sleep apnea, > 80% in those with a BMI > 40. Obesity has direct as well as indirect influences on upper airway mechanics and physiology. Obesity may also influence loop gain by exerting an influence on central chemosensory respiratory drive. Pattern of fat distribution rather than overall weight may have a modulatory effect on these influences. Obese patients also develop a syndrome of obesity-hypoventilation characterized by waketime hypercarbia, by mechanisms that are not entirely clear. Genetic mechanisms influencing obesity and OSA are bidirectional and likely exert mutually additive effects. Medical weight loss can be a treatment for OSA, but bariatric surgery has played an increasingly prominent role in the theraputic paradigm for OSA in the morbidly obese, with success rates of ∼85%.
Current Respiratory Medicine Reviews
Title: Obstructive Sleep Apnea and Obesity
Volume: 4 Issue: 2
Author(s): Shyam Subramanian and Kingman Strohl
Affiliation:
Abstract: Obesity trends continue to rise in alarming proportions worldwide. Obstructive sleep apnea, an increasingly commonly recognized disorder, is characterized by recurrent episodes of upper airway closure during sleep, and obesity is proposed to be its strongest risk factor. Recognition strategies for OSA in obesity are overwhelmed by the sheer prevalence of obstructive sleep apnea, > 80% in those with a BMI > 40. Obesity has direct as well as indirect influences on upper airway mechanics and physiology. Obesity may also influence loop gain by exerting an influence on central chemosensory respiratory drive. Pattern of fat distribution rather than overall weight may have a modulatory effect on these influences. Obese patients also develop a syndrome of obesity-hypoventilation characterized by waketime hypercarbia, by mechanisms that are not entirely clear. Genetic mechanisms influencing obesity and OSA are bidirectional and likely exert mutually additive effects. Medical weight loss can be a treatment for OSA, but bariatric surgery has played an increasingly prominent role in the theraputic paradigm for OSA in the morbidly obese, with success rates of ∼85%.
Export Options
About this article
Cite this article as:
Subramanian Shyam and Strohl Kingman, Obstructive Sleep Apnea and Obesity, Current Respiratory Medicine Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339808784222614
DOI https://dx.doi.org/10.2174/157339808784222614 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends in the Design and Application of Optical Chemosensors in Pharmaceutical and Biomedical Analysis
Current Pharmaceutical Analysis Current Biology of MTP: Implications for Selective Inhibition
Current Topics in Medicinal Chemistry Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Fc-independent Phagocytosis: Implications for IVIG and other Therapies in Immune-mediated Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders